Single-dose interaction study of diprafenone HCl and propranolol HCl in healthy volunteers
| Autor: | Peter H. Hinderling, Michael Seiberling, Cathryn M. Dee, Amol Tendolkar, William H. Barr, Helga Duerr |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male Adolescent Rest Propranolol Pharmacology Sensitivity and Specificity Drug Administration Schedule chemistry.chemical_compound Electrocardiography Pharmacokinetics Propafenone Oral administration Heart Rate Heart rate Medicine Humans Pharmacology (medical) Drug Interactions Diprafenone business.industry Drug interaction Drug Combinations Tolerability chemistry Pharmacodynamics Exercise Test business Anti-Arrhythmia Agents medicine.drug Half-Life |
| Zdroj: | Journal of clinical pharmacology. 35(7) |
| ISSN: | 0091-2700 |
| Popis: | Using a 3 x 3 Latin Square design, a possible interaction between diprafenone HCl a class IC antiarrhythmic drug with nonspecific beta-antagonist activity and propranolol HCl was investigated in nine young, healthy, caucasian, male volunteers. The volunteers randomly received 3 single-dose treatments: (A) 200 mg DHCl, (B) 80 mg PHCl, and (C) 200 mg DHCl and 80 mg PHCl. Scheduled blood samples were taken and plasma concentrations of both diprafenone and propranolol were measured by sensitive and specific assay methods. Lead II electrocardiogram intervals at rest, heart rate during erect bicycle ergometry, and echocardiographic variables at rest and shortly after exercise were recorded. The data analysis used compartment model independent methods. There was no evidence for a pharmacokinetic interaction between the two drugs. With DHCl, two of the nine subjects showed greatly increased areas under the plasma concentration-time curves and apparent disposition half-lives in the presence and absence of PHCl, indicating that metabolism of diprafenone may be subject to pharmacogenetic polymorphism. There was evidence for a pharmacodynamic interaction between DHCl and PHCl regarding the negative chronotropic effect at rest and during exercise. There was no difference in the pharmacodynamics and tolerability of the three treatments in suspected "poor" and "extensive metabolizers" of DHCl. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text